Fate Therapeutics, Inc. (FATE)
Largest Insider Buys in Sector
FATE Stock Price History Chart
FATE Stock Performance
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Activity of Fate Therapeutics, Inc.
Over the last 12 months, insiders at Fate Therapeutics, Inc. have bought $166,024 and sold $361,084 worth of Fate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fate Therapeutics, Inc. have bought $35.18M and sold $25.46M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Redmile Group, LLC () — $1.99M.
The last purchase of 44,630 shares for transaction amount of $166,024 was made by Redmile Group, LLC () on 2023‑12‑26.
List of Insider Buy and Sell Transactions, Fate Therapeutics, Inc.
| 2024-03-04 | Sale | Dulac Edward J III | Chief Financial Officer | 2,447 0.0027% | $7.77 | $19,013 | -40.96% | |
| 2024-01-29 | Sale | Dulac Edward J III | Chief Financial Officer | 1,849 0.0017% | $5.00 | $9,245 | -0.22% | |
| 2024-01-09 | Sale | Wolchko J Scott | President and CEO | 14,391 0.0145% | $4.37 | $62,889 | +8.96% | |
| 2024-01-09 | Sale | Valamehr Bahram | Chief R&D Officer | 11,271 0.0114% | $4.38 | $49,367 | +8.96% | |
| 2024-01-09 | Sale | TAHL CINDY | General Counsel and Secretary | 10,874 0.0109% | $4.37 | $47,519 | +8.96% | |
| 2024-01-09 | Sale | Dulac Edward J III | Chief Financial Officer | 7,028 0.0071% | $4.37 | $30,712 | +8.96% | |
| 2024-01-02 | Sale | Dulac Edward J III | Chief Financial Officer | 5,182 0.0052% | $3.66 | $18,966 | +30.08% | |
| 2023-12-26 | Redmile Group, LLC | 44,630 0.0455% | $3.72 | $166,024 | +22.89% | |||
| 2023-12-18 | Sale | Dulac Edward J III | Chief Financial Officer | 1,585 0.0018% | $3.50 | $5,548 | +43.76% | |
| 2023-11-09 | Sale | TAHL CINDY | General Counsel and Secretary | 24,363 0.0278% | $2.40 | $58,471 | +93.93% | |
| 2023-08-18 | Sale | Dulac Edward J III | Chief Financial Officer | 4,718 0.0048% | $2.80 | $13,210 | +33.09% | |
| 2023-08-04 | Sale | Xu Yuan | director | 632 0.0006% | $3.71 | $2,345 | -1.74% | |
| 2023-07-05 | Sale | Dulac Edward J III | Chief Financial Officer | 5,182 0.0053% | $4.83 | $25,029 | -22.69% | |
| 2023-07-05 | Sale | Powl Brian T. | Chief Commercial Officer | 3,854 0.0039% | $4.87 | $18,769 | -22.69% | |
| 2023-06-14 | Sale | Xu Yuan | director | 3,460 0.0036% | $5.58 | $19,307 | -28.91% | |
| 2023-04-21 | Redmile Group, LLC | 256,639 0.26% | $6.18 | $1.59M | -27.09% | |||
| 2023-04-20 | Redmile Group, LLC | 20,000 0.0204% | $5.99 | $119,800 | -24.29% | |||
| 2023-04-18 | Sale | Chu Yu-Waye | Chief Medical Officer | 2,532 0.0027% | $6.57 | $16,648 | -26.97% | |
| 2023-04-14 | Sale | Redmile Group, LLC | 302,339 0.2996% | $5.84 | $1.77M | -24.54% | ||
| 2023-04-14 | Redmile Group, LLC | 25,700 0.0262% | $6.00 | $154,200 | -24.54% |
Insider Historical Profitability
| Redmile Group, LLC | 13180388 13.3673% | $3.26 | 8 | 1 | +12.66% | |
| Wolchko J Scott | President and CEO | 371248 0.3765% | $3.26 | 0 | 37 | |
| Valamehr Bahram | Chief R&D Officer | 158069 0.1603% | $3.26 | 0 | 17 | |
| TAHL CINDY | General Counsel and Secretary | 142361 0.1444% | $3.26 | 0 | 25 | |
| Dulac Edward J III | Chief Financial Officer | 101479 0.1054% | $3.26 | 0 | 13 | |
| Powl Brian T. | Chief Commercial Officer | 41146 0.0417% | $3.26 | 0 | 1 | |
| Xu Yuan | director | 9302 0.0094% | $3.26 | 0 | 2 | |
| NELSEN ROBERT | 2473188 2.5083% | $3.26 | 1 | 0 | <0.0001% | |
| ARCH VENTURE FUND VI LP | 10 percent owner | 2473188 2.5083% | $3.26 | 1 | 0 | <0.0001% |
| VENROCK ASSOCIATES V LP | 10 percent owner | 2473187 2.5083% | $3.26 | 1 | 0 | <0.0001% |
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 2473186 2.5083% | $3.26 | 1 | 0 | <0.0001% |
| RASTETTER WILLIAM H | director | 459272 0.4658% | $3.26 | 2 | 0 | +1.02% |
| MENDLEIN JOHN | director | 282770 0.2868% | $3.26 | 3 | 2 | <0.0001% |
| Chu Yu-Waye | Chief Medical Officer | 140676 0.1427% | $3.26 | 0 | 6 | |
| Plavsic Mark | Chief Technical Officer | 123705 0.1255% | $3.26 | 0 | 2 | |
| Shoemaker Daniel D | Chief Scientific Officer | 73020 0.0741% | $3.26 | 0 | 13 | |
| COUGHLIN TIMOTHY | 57632 0.0584% | $3.26 | 1 | 1 | +11.55% | |
| Storgard Chris | Chief Medical Officer | 37593 0.0381% | $3.26 | 1 | 0 | +11.55% |
| Nashat Amir | director | 7539 0.0076% | $3.26 | 1 | 20 | <0.0001% |
| Flynn Peter D | See remarks | 4039 0.0041% | $3.26 | 0 | 8 | |
| HERSHBERG ROBERT | 2009 0.002% | $3.26 | 0 | 1 | ||
| Agarwal Shefali | 1840 0.0019% | $3.26 | 0 | 2 | ||
| Jooss Karin | 1198 0.0012% | $3.26 | 0 | 1 | ||
| Weyer Christian | See remarks | 0 0% | $3.26 | 0 | 2 |
Institutional Investor Ownership
| Redmile Group | $96.66M | 11.57 | 13.17M | 0% | +$0 | 3.58 | |
| The Vanguard Group | $72.75M | 8.71 | 9.91M | +6.65% | +$4.53M | <0.01 | |
| BlackRock | $66.79M | 7.99 | 9.1M | -18.84% | -$15.51M | <0.01 | |
| Boxer Capital, LLC | $60.3M | 7.22 | 8.22M | +1,543.18% | +$56.63M | 3.02 | |
| State Street | $58.99M | 7.06 | 8.04M | +331.63% | +$45.32M | <0.01 | |
| Deep Track Capital Lp | $40.9M | 4.89 | 5.57M | New | +$40.9M | 0.19 | |
| Bellevue Group | $35.52M | 4.25 | 4.84M | -0.24% | -$86,612.00 | 0.54 | |
| Johnson & Johnson | $24.8M | 2.97 | 3.38M | 0% | +$0 | 0.56 | |
| Citadel Advisors LLC | $22.99M | 2.75 | 3.13M | +17.45% | +$3.42M | 0.02 | |
| Morgan Stanley | $22.5M | 2.69 | 3.07M | +132.02% | +$12.8M | <0.01 | |
| D. E. Shaw & Co. | $20.05M | 2.4 | 2.73M | -23.76% | -$6.25M | 0.03 | |
| Suvretta Capital Management, LLC | $18.81M | 2.25 | 2.56M | New | +$18.81M | 0.79 | |
| Assenagon Asset Management S.A. | $18.7M | 2.24 | 2.55M | +1,462.45% | +$17.51M | 0.05 | |
| Holocene Advisors, LP | $18.55M | 2.22 | 2.53M | New | +$18.55M | 0.07 | |
| Deerfield Management | $16.08M | 1.92 | 2.19M | New | +$16.08M | 0.31 | |
| Adage Capital Partners Gp L L C | $15.71M | 1.88 | 2.14M | +25.88% | +$3.23M | 0.03 | |
| Goldman Sachs | $14.77M | 1.77 | 2.01M | +240.49% | +$10.43M | <0.01 | |
| Jacobs Levy Equity Management | $14.68M | 1.76 | 2M | -23.58% | -$4.53M | 0.07 | |
| Bank of America | $14.09M | 1.69 | 1.92M | +216.27% | +$9.64M | <0.01 | |
| Geode Capital Management | $13.99M | 1.67 | 1.91M | +2.28% | +$311,980.04 | <0.01 | |
| Woodline Partners LP | $13.89M | 1.66 | 1.89M | +390.96% | +$11.06M | 0.13 | |
| Baker Bros Advisors LP | $13.35M | 1.6 | 1.82M | New | +$13.35M | 0.17 | |
| JPMorgan Chase | $12.91M | 1.55 | 1.76M | -15.11% | -$2.3M | <0.01 | |
| Acadian Asset Management | $12.58M | 1.51 | 1.71M | -24.86% | -$4.16M | 0.04 | |
| Point72 Asset Management | $11.63M | 1.39 | 1.58M | -54.59% | -$13.98M | 0.02 | |
| Two Sigma Advisers LP | $10.55M | 1.26 | 1.44M | -23.4% | -$3.22M | 0.02 | |
| OrbiMed | $9.95M | 1.19 | 1.36M | +156.66% | +$6.07M | 0.2 | |
| Dimensional Fund Advisors | $7.8M | 0.93 | 1.06M | +231.44% | +$5.45M | <0.01 | |
| Federated Hermes | $7.39M | 0.89 | 1.01M | -45.54% | -$6.18M | 0.02 | |
| Invesco | $7.09M | 0.85 | 965,431 | +645.77% | +$6.14M | <0.01 | |
| Charles Schwab | $7.02M | 0.84 | 956,331 | -2.71% | -$195,889.93 | <0.01 | |
| Schonfeld Group | $6.51M | 0.78 | 886,925 | +78.29% | +$2.86M | 0.05 | |
| Soleus Capital Management, L.P. | $6.39M | 0.76 | 870,000 | New | +$6.39M | 0.06 | |
| Rafferty Asset Management Llc | $5.36M | 0.64 | 729,657 | New | +$5.36M | 0.02 | |
| Northern Trust | $5.26M | 0.63 | 716,052 | +1.05% | +$54,778.42 | <0.01 | |
| Tang Capital Management, LLC | $5.14M | 0.62 | 700,000 | 0% | +$0 | 0.02 | |
| Citigroup | $4.57M | 0.55 | 623,058 | -26.18% | -$1.62M | <0.01 | |
| Octagon Capital Advisors LP | $3.82M | 0.46 | 520,800 | New | +$3.82M | 0.5 | |
| Gcm Grosvenor Holdings Llc | $3.64M | 0.44 | 495,916 | 0% | +$0 | 0.56 | |
| Hudson Bay Capital Management LP | $3.38M | 0.4 | 460,000 | New | +$3.38M | 0.04 | |
| UBS | $3.26M | 0.39 | 444,050 | +151.87% | +$1.97M | <0.01 | |
| Prudential Financial | $2.81M | 0.34 | 383,201 | -31.57% | -$1.3M | <0.01 | |
| Voloridge Investment Management, LLC | $2.78M | 0.33 | 378,608 | New | +$2.78M | 0.01 | |
| Artal Group S A | $2.64M | 0.32 | 360,311 | New | +$2.64M | 0.01 | |
| Marshall Wace | $2.54M | 0.3 | 345,437 | New | +$2.54M | <0.01 | |
| Barclays | $2.38M | 0.29 | 324,243 | -9.78% | -$257,874.99 | <0.01 | |
| Monaco Asset Management Sam | $2.33M | 0.28 | 316,805 | -85.49% | -$13.7M | 1.07 | |
| BNY Mellon | $2.22M | 0.27 | 301,993 | -6.2% | -$146,499.02 | <0.0001 | |
| Nuveen | $2.2M | 0.26 | 299,656 | -4.74% | -$109,476.10 | <0.01 | |
| Caxton Associates | $2.13M | 0.26 | 290,187 | New | +$2.13M | 0.15 |